More research on the benefits of Quatrefolic®! This study set out to determine if Quatrefolic® was effective at reducing homocysteine levels in people with a polymorphism at MTHFR C677T.
Homocysteine is an amino acid that can build up in the blood and hyperhomocysteinaemia (high homocysteine levels) is the most common thrombophilia (a tendency towards blood clots). In pregnant women, this tendency towards blood clots increases her risk of miscarriage.
According to the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), 1.5% of the population is homozygous (inherited from both parents) and 25% are heterozygous (inherited from one parent). RANZCOG state that this “thrombophilic tendency is minimised by an adequacy of folate, riboflavin (vitamin B2), vitamin B6 and vitamin B12”.
The participants in the study were 89 couples with fertility problems for at least 3 years. As expected, prior to treatment, homocysteine levels were higher in the homozygous patients than in the heterozygous patients.
Couples were treated with 600mcg of Quatrefolic® for 3 months. Both groups were found to have a statistically significant reduction in homocysteine with a substantial reduction in the homozygous group.
This study backs up the results of another study using Quatrefolic® conducted last year. Couples with MTHFR C677T polymorphisms experiencing recurrent miscarriages were treated with 800mcg of Quatrefolic®. You can find the results of the study here.
- Clément A, Menezo Y, Cohen M, Cornet D, Clément P. 5-Methyltetrahydrofolate reduces blood homocysteine level significantly in C677T methyltetrahydrofolate reductase single-nucleotide polymorphism carriers consulting for infertility. J Gynecol Obstet Hum Reprod. 2020
- RANZCOG, Vitamin and Mineral Supplementation and Pregnancy, November 2019.